Abbott Laboratories expected to post earnings of $1.10 a share - Earnings Preview Abbott Laboratories ABT.N , ABT is expected to show a rise in quarterly revenue when it reports results on July 18 for the period ending June 30 2024 The Abbott Park Illinois-based company is expected to report a 3.9% increase in revenue to $10.371 billion from $9.98 billion a year ago, according to the mean estimate from 19 analysts, based on LSEG data.

What to Watch in the Week Ahead and on Monday, July 15 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Federal Reserve Chair Jerome Powell is set to participate in a conversation hosted by the Economic Club of Washington.

AbbVie asks US Supreme Court to weigh protections for attorney records By Mike Scarcella July 11 (Reuters) - Pharmaceutical company AbbVie ABBV.N has asked the U.S. Supreme Court to take up its fight to protect corporate records, warning that a lower court ruling threatens to erode the shield that keeps most attorney communications off-limits from a company's courtroom opponents.

First trial against Abbott over premature infant formula kicks off in Missouri By Brendan Pierson July 9 (Reuters) - The first trial against Similac baby formula maker Abbott ABT.N over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease got underway with opening statements on Tuesday, as a lawyer for a mother suing the company urged jurors to hold it liable for her child's lifelong injuries.

Abbott faces trial over claims that preterm infant formula caused dangerous disease By Brendan Pierson July 8 (Reuters) - Similac baby formula maker Abbott ABT.N is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.

Bain-backed Emcure Pharma's $234 mln India IPO draws $11 bln in bids By VarunVyas Hebbalalu and Kashish Tandon BENGALURU, July 5 (Reuters) - India's Emcure Pharmaceuticals EMCU.NS drew strong interest for its $234 million initial public offering (IPO) as investors bet on its slate of women's healthcare and HIV treatments to drive growth in a high-margin market.

BRIEF-FDA Says Abbott Medical Issues Correction For Heartmate LVAS System Monitor Due To Screen Issues That May Cause Unintentional Pump Stop June 28 (Reuters) - FDA: FDA: ABBOTT MEDICAL ISSUES CORRECTION FOR HEARTMATE LVAS SYSTEM MONITOR DUE TO SCREEN ISSUES THAT MAY CAUSE UNINTENTIONAL PUMP STOP FDA: THERE HAVE BEEN 14 REPORTED INJURIES, NO REPOR

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals Repeats to wider addresses, no changes to text By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. Continuous glucose monitors or CGMs were developed for use by diabetes patients but their makers, led by Abbott ABT.N and Dexcom DXCM.O , also spy oppo

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals Updates to add U.S. approval of Abbott's prescription-free CGMs in paragraphs 10, 11 By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels.

UPDATE 3-Abbott secures FDA clearance for two over-the-counter glucose monitors Adds analyst comment in paragraphs 4 and 8, shares in paragraph 10 By Pratik Jain and Sriparna Roy June 10 (Reuters) - Abbott Laboratories ABT.N said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing, multi-billion-dollar market.

US FDA clears Abbott's continuous glucose monitors for over-the-counter use June 10 (Reuters) - Abbott ABT.N said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use. Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber

FOCUS-Olympic athletes turn to diabetes tech in pursuit of medals By Ludwig Burger June 10 (Reuters) - Olympians including Dutch marathon runner Abdi Nageeye are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. Continuous glucose monitors or CGMs, were developed for use by diabetes patients but their makers, led by Abbott ABT.N and Dexcom DXCM.O , also spy opportunities in sports and wellness.

FACTBOX-Why are top athletes using diabetes tech in pursuit of medals? June 10 (Reuters) - Some Olympic athletes are using a new tool they hope will boost their medal chances this summer: tiny monitors that attach to the skin to track blood glucose levels. The market for continuous glucose monitors (CGMs), developed to help diabetes patients fine-tune their insulin shots, is already worth billions of dollars per year.

BUZZ-U.S. STOCKS ON THE MOVE-Semtech, United Rentals, Toro Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes dropped on Friday after a much stronger-than-expected employment report signaled that the labor market remains robust, dimming hopes of a September start to policy easing by the U.S.

Abbott Laboratories loses bid to halt Glucerna class action By Diana Novak Jones June 6 (Reuters) - Litigation claiming that Abbott Laboratories is marketing Glucerna shakes and nutritional powders with harmful ingredients can move forward, a California federal judge said Wednesday. U.S. District Judge P. Casey Pitts in San Jose largely rejected Abbott’s motion to dismiss the proposed class action, ruling that the consumers had provided enough evidence at this stage to support their claims tha

U.S. RESEARCH ROUNDUP-Connectone Bancorp, Hormel Foods, UMB Financial May 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Connectone Bancorp, Hormel Foods and UMB Financial, on Friday. HIGHLIGHTS * Connectone Bancorp Inc CNOB.O : KBW cuts to market perform from outperform * Hancock Whitney Corp HWC.O : KBW raises to outperform from market perform * Hormel Foods Corp HRL.N : JP Morgan raises to neutral from underwe

U.S. FDA set to reorganize its food division starting October May 30 (Reuters) - The U.S. Food and Drug Administration(FDA) said on Thursday it plans to restructure its food division starting in October helping it to oversee human food supply chains and agricultural products more efficiently. The regulatory body had come under fire over its slow response to the infant formula shortage in 2022. WHY IT'S IMPORTANT The FDA said the reorganization will enable it to be more efficient and agile while

UPDATE 4-Medtronic's weaker-than-expected outlook clouds quarterly results beat Adds CFO comments in paragraphs 5 and 10, graphic By Pratik Jain and Christy Santhosh May 23 (Reuters) - Medtronic MDT.N beat estimates for fourth-quarter revenue and profit on Thursday, helped by robust sales of its medical devices, but shares declined more than 3% after its forecast for the current quarter fell short of Wall Street expectations.

U.S. RESEARCH ROUNDUP-Ameriprise Financial, Dell Technologies, Stryker May 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ameriprise Financial, Dell Technologies and Stryker, on Wednesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : Jefferies raises target price to $500 from $487 * Bio-Techne Corp TECH.O : Citigroup cuts to neutral from buy * Dell Technologies Inc DELL.N : Raymond James raises target price to $

GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales BENGALURU, May 17 (Reuters) - Drugmaker GlaxoSmithKline Pharma India GLAX.NS reported a 49% rise in fourth-quarter adjusted profit on Friday , as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. The company reported consolidated profit before exceptional items and taxes of 2.68 billion rupees ($32.1 million) for the quarter ended March 31, compared to 1.